Authors:
Duhmke, E
Franklin, J
Pfreundschuh, M
Sehlen, S
Willich, N
Ruhl, U
Muller, RP
Lukas, P
Atzinger, A
Paulus, U
Lathan, B
Ruffer, U
Sieber, M
Wolf, J
Engert, A
Georgii, A
Staar, S
Herrmann, R
Beykirch, M
Kirchner, H
Emminger, A
Greil, R
Fritsch, E
Koch, P
Drochtert, A
Brosteanu, O
Hasenclever, D
Loeffler, M
Diehl, V
Citation: E. Duhmke et al., Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone, J CL ONCOL, 19(11), 2001, pp. 2905-2914
Citation: M. Sieber et al., Treatment of Hodgkin's disease: Current strategies of the German Hodgkin'sLymphoma Study Group (vol 10, pg S23, 1999), ANN ONCOL, 11(6), 2000, pp. 765-765
Citation: M. Sieber et al., Treatment of Hodgkin's disease: Current strategies of the German Hodgkin'sLymphoma Study Group, ANN ONCOL, 10, 1999, pp. 23-29
Authors:
Tesch, H
Diehl, V
Lathan, B
Hasenclever, D
Sieber, M
Ruffer, U
Engert, A
Franklin, J
Pfreundschuh, M
Schalk, KP
Schwieder, G
Wulf, G
Dolken, G
Worst, P
Koch, P
Schmitz, N
Bruntsch, U
Tirier, C
Muller, U
Loeffler, M
Citation: H. Tesch et al., Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: A study of the German Hodgkin's Lymphoma Study Group, BLOOD, 92(12), 1998, pp. 4560-4567